1 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Unresectable Thyroid Gland Carcinoma: new trials by email Literature Review of Unresectable Thyroid Gland Carcinoma trials Research Report on Unresectable Thyroid Gland Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2013-09-27 | 2026-05-14 |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 127 | 2010-09-09 | 2021-07-15 |
Adenocarcinoma, Follicular (1) · Thyroid Cancer, Papillary (1) · Thyroid Neoplasms (1) · Thyroid cancer, Hurthle cell (1)
Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Thyroid Diseases (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Thyroid Neoplasms (1)
Biopsy (1) · Lapatinib (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (1) · Specimen Handling (1) · cediranib (1) · dabrafenib (1)
National Cancer Institute (NCI) (2)
United States (2) · Canada (1)
Chih-Yi Liao (1) · Eric J Sherman (1)
N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), P30CA008748 (1), P30CA014599 (1), U01CA069856 (1), U10CA180821 (1)